Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma

The treatment landscape of metastatic urothelial cancer (mUC) remained unchanged for over 30 years until the approval of immune checkpoint inhibitors (ICIs) in 2016. Since then, several ICIs have been approved for the treatment of mUC. In addition, recent molecular characterization of bladder cancer...

Descripción completa

Detalles Bibliográficos
Autores principales: Benjamin, David J, Mar, Nataliya, Rezazadeh Kalebasty, Arash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520173/
https://www.ncbi.nlm.nih.gov/pubmed/36186672
http://dx.doi.org/10.1177/11795549221126252

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9520173/
https://www.ncbi.nlm.nih.gov/pubmed/36186672
http://dx.doi.org/10.1177/11795549221126252

Ejemplares similares